Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 11 articles:
HTML format



Single Articles


    November 2021
  1. SACHS RE, Bagley N
    Medicare Coverage of Aducanumab - Implications for State Budgets.
    N Engl J Med. 2021;385:2019-2021.
    PubMed    


  2. ROBINSON JC
    Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    N Engl J Med. 2021;385:2017-2019.
    PubMed    


    August 2021
  3. ALEXANDER GC, Knopman DS, Emerson SS, Ovbiagele B, et al
    Revisiting FDA Approval of Aducanumab.
    N Engl J Med. 2021;385:769-771.
    PubMed    


  4. MINTUN MA, Wessels AM, Sims JR
    Donanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2021;385:667.
    PubMed    


  5. ESPAY AJ
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021;385:666-667.
    PubMed    


    July 2021
  6. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    PubMed    


  7. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    PubMed    


    May 2021
  8. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    PubMed    


    March 2021
  9. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    PubMed     Abstract available


    October 2020
  10. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    PubMed    


    June 2020
  11. INGELFINGER JR
    Kinder, Gentler Dementia-Friendly Alzheimer's Care.
    N Engl J Med. 2020;382:2487-2489.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: